- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr. Margaret K. Pasquale and Team Identify High-Risk Factors Predicting Opioid Abuse
Margaret K. Pasquale, PhD, principal researcher, Comprehensive Health Insights at Humana, says Humana's predictive model of opioid abuse suggests that there are a few factors that might lend people to be at high risk for opioid abuse
lend people to be at high risk for opioid abuse.
Margaret K. Pasquale, PhD, principal researcher, Comprehensive Health Insights at Humana, says Humana’s predictive model of opioid abuse suggests that there are a few factors that might
“Our model was capturing not just patient behavior, but also provider behavior, and maybe some systemic inefficiencies that might exist. It found that there are a couple of different domains where people lend themselves to be at high risk,” Dr Pasquale said.
The model found that characteristics predicting for opioid abuse may include prescription use of opioids, and psychological diagnoses such as neuropathic pain, anxiety, or depression.
Dr Pasquale's research was sponsored by the Humana-Pfizer Research Collaboration. For a copy of the poster presented at AMCP, please contact
.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
